Formulation, Characterization, and Preliminary In Vitro Evaluation of Letrozole Incorporated Eudragit® RS 100 Nanoparticles Using HepG2 Cells
4 affiliations
- 1Anadolu University, Institute of Graduate Education, 26470, Eskisehir, Türkiye
- 2Department of Pharmaceutical Technology, Faculty of Pharmacy, Anadolu University, 26470, Eskisehir, Türkiye
- 3Department of Pharmaceutical Technology, Faculty of Pharmacy, Erzincan Binali Yıldırım University, Erzincan, Türkiye
- 4Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Anadolu University, 26470, Eskisehir, Türkiye
Abstract
Introduction/objective: Letrozole (LTZ)-loaded polymeric nanoparticles (PNPs) were formulated with Eudragit® RS100 to investigate their potential as a preliminary drug delivery system for hepatocellular carcinoma (HCC).
Methods: Nanoparticles were prepared using the spray-drying technique with a Büchi B-90 Nano Spray Dryer and characterized in terms of morphology, particle size, polydispersity index (PDI), zeta potential, drug loading efficiency, thermal and structural characteristics, in vitro release behavior, and preliminary cytotoxicity.
Results: Scanning electron microscopy (SEM) analysis demonstrated the formation of predominantly spherical particles with relatively smooth surfaces. The prepared nanoparticles exhibited initial particle sizes ranging between 253 nm and 425 nm, with PDI values of 0.3–0.4 and positive zeta potential values between 36 and 48 mV. Encapsulation efficiency (EE%) and drug loading (DL%) values were determined as 47.9%–56.9% and 9.1%–18.6%, respectively. Thermal and structural analyses indicated the molecular dispersion of LTZ within the polymeric matrix. In vitro release studies conducted at pH 7.4 demonstrated an initial burst release, followed by a sustained drug release profile over 24 h, with cumulative drug release reaching almost 80%. The preliminary cytotoxicity of the formulations was evaluated using the methylthiazolyl-diphenyl-tetrazolium bromide (MTT) assay on human hepatocellular carcinoma (HepG2) and healthy human dermal fibroblast (BJ) cell lines. Free LTZ demonstrated an IC50 value of 142.76 μg/mL against HepG2 cells, whereas the optimized nanoparticle formulation exhibited an IC50 value higher than 121.85 μg/mL.
Discussion: The obtained results confirmed the successful development of LTZ-loaded polymeric nanoparticles with suitable physicochemical properties, efficient drug encapsulation, and sustained release behavior. The positive surface charge and nanoscale size may support formulation stability. Furthermore, the nanoparticles preserved the cytotoxic activity of LTZ, indicating their potential as an effective drug delivery system.
Conclusion: Overall, the findings suggest that the developed nanoparticles constitute a promising drug delivery system for further investigation in HCC-related therapy. However, additional mechanistic studies and in vivo evaluations are required to comprehensively assess their true therapeutic potential.
Related
- Comparative evaluation of green-synthesized CeO2-rich and multi-rare-earth-containing oxide-rich nanoparticles prepared using Moringa oleifera seed extract: physicochemical characterization and preliminary cell-free screening
- Evaluation of Tagetes erecta-incorporated Ag–Co bimetallic nano particles: characterization and enhancement of their antibacterial, antioxidant, and cytotoxic activities using an in vitro approach
- Benzothiazole–Triazole–Indazole Conjugates: Design, Characterization, and Preliminary In Vitro MTT-Based Antiproliferative Evaluation
- Phytogenic Synthesis of Platinum Nanoparticles: Characterization and In Vitro Biological Evaluation of Antioxidant, Antimicrobial, and Anticancer Activities.
- Green synthesis and characterization of Bi₂O₃ nanoparticles using Cuminum cyminum seed for antimicrobial and cytotoxic evaluation.
BibTeX
@article{polat2026formulation,
title = {{Formulation, Characterization, and Preliminary In Vitro Evaluation of Letrozole Incorporated Eudragit® RS 100 Nanoparticles Using HepG2 Cells}},
author = {Muhammet Ali Polat and Kadir Aykaç and Zerrin Cantürk and Ebru Başaran},
journal = {Current Pharmaceutical Design},
year = {2026},
month = oct,
doi = {10.2174/0113816128474280260720051151},
url = {https://doi.org/10.2174/0113816128474280260720051151},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Formulation, Characterization, and Preliminary In Vitro Evaluation of Letrozole Incorporated Eudragit® RS 100 Nanoparticles Using HepG2 Cells
AU - Muhammet Ali Polat
AU - Kadir Aykaç
AU - Zerrin Cantürk
AU - Ebru Başaran
PY - 2026
DA - 2026/10/27
JO - Current Pharmaceutical Design
DO - 10.2174/0113816128474280260720051151
UR - https://doi.org/10.2174/0113816128474280260720051151
AB - Introduction/objective: Letrozole (LTZ)-loaded polymeric nanoparticles (PNPs) were formulated with Eudragit® RS100 to investigate their potential as a preliminary drug delivery system for hepatocellular carcinoma (HCC). Methods: Nanoparticles were prepared using the spray-drying technique with a Büchi B-90 Nano Spray Dryer and characterized in terms of morphology, particle size, polydispersity index (PDI), zeta potential, drug loading efficiency, thermal and structural characteristics, in vitro release behavior, and preliminary cytotoxicity. Results: Scanning electron microscopy (SEM) analysis demonstrated the formation of predominantly spherical particles with relatively smooth surfaces. The prepared nanoparticles exhibited initial particle sizes ranging between 253 nm and 425 nm, with PDI values of 0.3–0.4 and positive zeta potential values between 36 and 48 mV. Encapsulation efficiency (EE%) and drug loading (DL%) values were determined as 47.9%–56.9% and 9.1%–18.6%, respectively. Thermal and structural analyses indicated the molecular dispersion of LTZ within the polymeric matrix. In vitro release studies conducted at pH 7.4 demonstrated an initial burst release, followed by a sustained drug release profile over 24 h, with cumulative drug release reaching almost 80%. The preliminary cytotoxicity of the formulations was evaluated using the methylthiazolyl-diphenyl-tetrazolium bromide (MTT) assay on human hepatocellular carcinoma (HepG2) and healthy human dermal fibroblast (BJ) cell lines. Free LTZ demonstrated an IC50 value of 142.76 μg/mL against HepG2 cells, whereas the optimized nanoparticle formulation exhibited an IC50 value higher than 121.85 μg/mL. Discussion: The obtained results confirmed the successful development of LTZ-loaded polymeric nanoparticles with suitable physicochemical properties, efficient drug encapsulation, and sustained release behavior. The positive surface charge and nanoscale size may support formulation stability. Furthermore, the nanoparticles preserved the cytotoxic activity of LTZ, indicating their potential as an effective drug delivery system. Conclusion: Overall, the findings suggest that the developed nanoparticles constitute a promising drug delivery system for further investigation in HCC-related therapy. However, additional mechanistic studies and in vivo evaluations are required to comprehensively assess their true therapeutic potential.
SN - 1381-6128
SN - 1873-4286
ER -